Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10308343 | 0.81 | HMGCR (0.33) | HMGCRCHRM1TBXA2RADRA1APIK3CD | |
| SCHEMBL10308339 | 0.81 | HMGCR (0.33) | HMGCRCHRM1TBXA2RADRA1APIK3CD | |
| SCHEMBL10308379 | 0.81 | HMGCR (0.33) | HMGCRCHRM1TBXA2RADRA1APIK3CD | |
| SCHEMBL13043705 | 0.78 | ALDH1A1 (0.31) | ALDH1A1PIK3CD | |
| SCHEMBL5693007 | 0.78 | ALDH1A1 (0.31) | ALDH1A1PIK3CD | |
| SCHEMBL7917694 | 0.77 | PIK3CD (0.46) | HMGCRCHRM1TBXA2RADRA1AALDH1A1 | |
| SCHEMBL7910108 | 0.74 | HMGCR (0.33) | HMGCRCHRM1TBXA2RADRA1ATSHR | |
| SCHEMBL10308344 | 0.74 | KDM4E (0.33) | HMGCRCHRM1TBXA2RADRA1ATSHR | |
| SCHEMBL12836892 | 0.74 | ALDH1A1 (0.40) | HMGCRCHRM1TBXA2RADRA1AALDH1A1 | |
| SCHEMBL11161149 | 0.73 | PIK3CD (0.39) | HMGCRCHRM1TBXA2RADRA1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110028552-A1 | MEXILETINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028552-A1 | MEXILETINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | VIP, TRPV1, LNPEP | HMGCR 2170/4885CHRM1 1474/4885TBXA2R 3642/4885 |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | HMGCR 2694/4885CHRM1 1860/4885TBXA2R 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.